넥스트큐어 (NXTC) 주가

넥스트큐어(NXTC)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $8.21 (-0.85%), 시가총액 $0.04B, 52주 범위 $0.40 ~ $14.27.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC)

핵심 지표

• 현재가: $8.21 (-0.85%)
• 시가총액: $0.04B
• 52주 최저~최고: $0.40 ~ $14.27
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

넥스트큐어의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.

넥스트큐어 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 1.33
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문